Publication | Closed Access

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseMedicineInsulin ManagementDiabetesCardiovascular RiskType 2Diabetes MellitusPharmacologyInsulin SignalingPhase 3